Compare GSK plc (GSK) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Tango Therapeutics Inc. — how do they compare? GSK plc trades at $47.87 (market cap $92.78B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: GSK plc is far larger — about 24.7× Tango Therapeutics Inc.'s market cap, and GSK plc pays a 3.92% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Tango Therapeutics Inc. for 0 Days on average.
| GSK | TNGX | |
|---|---|---|
Market Cap | $92.78B | $3.75B |
Volume | 5,756,402 | 9,619,106 |
Sector | Health | Health |
52-Week High | $61.18 | $32.90 |
52-Week Low | $43.24 | $7.50 |
Typical Hold Time | 93 Days | 0 Days |
Enterprise Value | $112.77B | $2.77B |
Dividend Yield | 3.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.87, up 2.02% today, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with 72.73% gross margins and 14.52% net income margin, supported by consistent revenue growth from $32.67B in 2025. Recent developments include a $750M cancer therapy acquisition and strategic focus on oncology expansion.
GSK presents a mixed outlook with solid fundamentals and strategic pipeline investments offset by technical weakness and patent cliff concerns. The stock offers value at 14.84 P/E but faces execution risks in oncology growth and HIV patent expirations. Analyst consensus leans cautious with 55% hold ratings.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
